Is a
Patent attributes
Patent Jurisdiction
Patent Number
Patent Inventor Names
John Stephen Bridgeman0
Date of Patent
October 15, 2024
0Patent Application Number
180683190
Date Filed
December 19, 2022
0Patent Primary Examiner
CPC Code
Patent abstract
The present invention discloses cell lines and recombinant growth factor receptors useful in adoptive cell therapy (ACT), wherein the recombinant growth factor receptor can act as a molecular switch enabling cells expressing the rGFR protein to be expanded in-vitro or in-vivo. Thus the invention provides a T or NK cell, comprising a recombinant growth factor receptor (rGFR) comprising: (i) an extracellular (EC) domain; (ii) a thrombopoietin receptor transmembrane (TM) domain; and (iii) a growth factor receptor intracellular (IC) domain.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.